Company Overview
Organogenesis Holdings Inc. operates within the healthcare sector, specifically functioning as a drug manufacturer within the specialty and generic industries. The company focuses on the development, manufacturing, and commercialization of products designed for the advanced wound care, surgical, and sports medicine markets across the United States. Its core portfolio includes advanced wound care solutions such as Affinity and Novachor, which are derived from amnion and chorion tissue. As of the latest data, the organization employs 854 individuals and holds a market capitalization of $313.88M. The company reported annual revenue of $564.17M over the trailing twelve months. These valuation and revenue figures indicate that Organogenesis is a mid-sized enterprise with significant operational scale within the regenerative medicine landscape. The combination of a specialized product line and a substantial workforce suggests a firm established enough to navigate the complex regulatory and commercial challenges inherent in the pharmaceutical and medical device sectors.
Financial Health
The organization reported revenue of $564.17M, a net income of $20.02M, and an EBITDA of $74.98M for the trailing twelve months. The substantial gap between revenue and net income highlights a significant cost structure where non-operating expenses or one-time charges impacted the bottom line, resulting in a profit margin of 6.6%. Free cash flow stands at $-50,102,376, indicating a period of negative liquidity generation which suggests the company is currently investing heavily in operations or growth initiatives rather than distributing excess cash. Gross margin is reported at 75.6%, reflecting the high-margin nature of its specialty medical products and efficient production costs relative to sales. Operating margin sits at 28.9%, demonstrating that the company retains a robust portion of revenue after covering the direct costs of generating sales and overhead expenses. The company holds $95.92M in cash against $82.14M in debt, resulting in a debt-to-equity ratio of 18.93. While the absolute debt level is lower than cash reserves, the high leverage ratio relative to equity implies a capital structure that relies heavily on shareholder financing or where equity is diluted. The current ratio is 3.62, which indicates a strong ability to meet short-term obligations with its liquid assets. Return on Equity is 9.0% and Return on Assets is 6.4%, metrics that reveal management's effectiveness in generating profits from the shareholders' capital and the total asset base, respectively.
Valuation Assessment
The trailing twelve-month P/E ratio is 16.27, while the forward P/E is 8.41. This significant disparity between the trailing and forward multiples implies that the market expects earnings growth that will drastically reduce the forward multiple, suggesting high anticipated growth in profitability. The price-to-book ratio is 1.03, indicating that the market values the company at just slightly more than its book value, which is often seen as a neutral or undervalued stance for a growth-oriented healthcare firm. Alternative valuation metrics include a price-to-sales ratio of 0.56 and an EV/EBITDA of 5.79. These alternative measures suggest that the company is trading at a discount relative to its sales and earnings before interest, taxes, depreciation, and amortization, which can be attractive for investors seeking value in a high-growth sector. The 52-week high is $7.08 and the 52-week low is $2.31. To calculate the current position relative to this range without a specific current price provided in the facts, the trading range is defined by these extremes, showing a wide band of volatility over the past year. The stock exhibits a beta of 1.39, meaning its price volatility is higher than the broader market, moving 39% more than the market index in response to systemic changes.
Growth & Income
Revenue growth over the past year is 78.1%, and earnings growth is 555.2%. Earnings are growing at a rate significantly faster than revenue, which implies that the company is achieving operational leverage or realizing substantial cost synergies as its sales volume expands. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not currently distribute dividends to shareholders. This non-dividend status indicates that Organogenesis reinvests all available earnings back into the business to fund research, development, and commercialization efforts rather than paying out income. The absence of a dividend yield confirms that the organization prioritizes capital allocation toward growth initiatives and product expansion over immediate income returns for investors. In summary, the company presents a high-growth profile characterized by accelerating profitability and a strategy of reinvestment rather than income distribution.